@inbook{050a414894514c55ac17bc55a15d0b3f,
title = "Pharmacological Treatments for Anhedonia",
abstract = "Anhedonia – the reduced ability to experience or respond to pleasure – is an important symptom domain for many psychiatric disorders. It is particularly relevant to depression and other mood disorders and it is a diagnostic criterion of a major depressive episode. Developing safe and effective pharmacological interventions for anhedonia is a critical public health need. The current chapter will review the state of the field with respect to both the efficacy of currently available pharma-cotherapies for anhedonia and the recent clinical research focusing on new brain targets, including the kappa-opioid receptor and the KCNQ2/3 receptors. The evidence for anti-anhedonic effects of ketamine and psychedelic agents will be reviewed, as well.",
keywords = "Anhedonia, Antidepressant, Depression, KCNQ, Ketamine, Opioid, Psychedelic, Reward",
author = "Klein, {Matthew E.} and Grice, {Ariela Buxbaum} and Sahil Sheth and Megan Go and Murrough, {James W.}",
note = "Publisher Copyright: {\textcopyright} 2022, Springer Science and Business Media Deutschland GmbH. All rights reserved.",
year = "2022",
doi = "10.1007/7854_2022_357",
language = "English",
series = "Current Topics in Behavioral Neurosciences",
publisher = "Springer Science and Business Media Deutschland GmbH",
pages = "467--490",
booktitle = "Current Topics in Behavioral Neurosciences",
address = "Germany",
}